EGFR G719X
|
NSCLC
|
EGFR G719X
|
NSCLC
|
afatinib Sensitive: B - Late Trials
|
afatinib Sensitive: B - Late Trials
|
EGFR G719X
|
NSCLC
|
EGFR G719X
|
NSCLC
|
osimertinib Sensitive: C2 – Inclusion Criteria
|
osimertinib Sensitive: C2 – Inclusion Criteria
|
EGFR G719X
|
NSCLC
|
EGFR G719X
|
NSCLC
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
EGFR G719X
|
NSCLC
|
EGFR G719X
|
NSCLC
|
gefitinib Sensitive: C2 – Inclusion Criteria
|
gefitinib Sensitive: C2 – Inclusion Criteria
|
EGFR G719X
|
LUAD
|
EGFR G719X
|
LUAD
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
EGFR G719X
|
NSCLC
|
EGFR G719X
|
NSCLC
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR G719X
|
NSCLC
|
EGFR G719X
|
NSCLC
|
Tyrosine kinase inhibitor Resistant: C3 – Early Trials
|
Tyrosine kinase inhibitor Resistant: C3 – Early Trials
|
EGFR G719X
|
Lung Cancer
|
EGFR G719X
|
Lung Cancer
|
pan-ErbB inhibitor Sensitive: D – Preclinical
|
pan-ErbB inhibitor Sensitive: D – Preclinical
|